(NASDAQ: INBX) Inhibrx Biosciences's forecast annual revenue growth rate of 367.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Inhibrx Biosciences's revenue in 2026 is $1,400,000.On average, 3 Wall Street analysts forecast INBX's revenue for 2026 to be $0, with the lowest INBX revenue forecast at $0, and the highest INBX revenue forecast at $0. On average, 3 Wall Street analysts forecast INBX's revenue for 2028 to be $1,448,498,130, with the lowest INBX revenue forecast at $1,391,690,289, and the highest INBX revenue forecast at $1,491,169,457.
In 2029, INBX is forecast to generate $1,917,300,981 in revenue, with the lowest revenue forecast at $1,842,109,855 and the highest revenue forecast at $1,973,730,684.